Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 187

1.

Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum.

Kapulu MC, Da DF, Miura K, Li Y, Blagborough AM, Churcher TS, Nikolaeva D, Williams AR, Goodman AL, Sangare I, Turner AV, Cottingham MG, Nicosia A, Straschil U, Tsuboi T, Gilbert SC, Long CA, Sinden RE, Draper SJ, Hill AV, Cohuet A, Biswas S.

Sci Rep. 2015 Jun 11;5:11193. doi: 10.1038/srep11193.

2.

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.

Alharbi NK, Spencer AJ, Hill AV, Gilbert SC.

PLoS One. 2015 Jun 8;10(6):e0128626. doi: 10.1371/journal.pone.0128626. eCollection 2015.

3.

Investigation of IRES Insertion into the Genome of Recombinant MVA as a Translation Enhancer in the Context of Transcript Decapping.

Alharbi NK, Chinnakannan SK, Gilbert SC, Draper SJ.

PLoS One. 2015 May 26;10(5):e0127978. doi: 10.1371/journal.pone.0127978. eCollection 2015.

4.

Corrections. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases.

Tully CM, Lambe T, Gilbert SC, Hill AV.

Lancet Infect Dis. 2015 Mar;15(3):263. doi: 10.1016/S1473-3099(14)70967-3. Epub 2015 Jan 20. No abstract available.

PMID:
25749220
5.

A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report.

Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, Payne R, Hartnell F, Gibani M, Bliss C, Minhinnick A, Wilkie M, Venkatraman N, Poulton I, Lella N, Roberts R, Sierra-Davidson K, Krähling V, Berrie E, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Becker S, Graham BS, Koup RA, Levine MM, Moorthy V, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV.

N Engl J Med. 2015 Jan 28. [Epub ahead of print]

6.

The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.

Dicks MD, Guzman E, Spencer AJ, Gilbert SC, Charleston B, Hill AV, Cottingham MG.

Vaccine. 2015 Feb 25;33(9):1121-8. doi: 10.1016/j.vaccine.2015.01.042. Epub 2015 Jan 25.

7.

Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies.

Hodgson SH, Douglas AD, Edwards NJ, Kimani D, Elias SC, Chang M, Daza G, Seilie AM, Magiri C, Muia A, Juma EA, Cole AO, Rampling TW, Anagnostou NA, Gilbert SC, Hoffman SL, Draper SJ, Bejon P, Ogutu B, Marsh K, Hill AV, Murphy SC.

Malar J. 2015 Jan 28;14:33. doi: 10.1186/s12936-015-0541-6.

8.

Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases.

Tully CM, Lambe T, Gilbert SC, Hill AV.

Lancet Infect Dis. 2015 Mar;15(3):356-9. doi: 10.1016/S1473-3099(14)71071-0. Epub 2015 Jan 14. Review. Erratum in: Lancet Infect Dis. 2015 Mar;15(3):263.

PMID:
25595637
9.

Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.

Pavot V, Berthet M, Rességuier J, Legaz S, Handké N, Gilbert SC, Paul S, Verrier B.

Nanomedicine (Lond). 2014 Dec;9(17):2703-18. doi: 10.2217/nnm.14.156.

PMID:
25529572
10.

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.

de Barra E, Hodgson SH, Ewer KJ, Bliss CM, Hennigan K, Collins A, Berrie E, Lawrie AM, Gilbert SC, Nicosia A, McConkey SJ, Hill AV.

PLoS One. 2014 Dec 18;9(12):e115161. doi: 10.1371/journal.pone.0115161. eCollection 2014.

11.

Immunity, safety and protection of an Adenovirus 5 prime--Modified Vaccinia virus Ankara boost subunit vaccine against Mycobacterium avium subspecies paratuberculosis infection in calves.

Bull TJ, Vrettou C, Linedale R, McGuinnes C, Strain S, McNair J, Gilbert SC, Hope JC.

Vet Res. 2014 Oct 29;45:112. doi: 10.1186/s13567-014-0112-9.

12.

Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.

Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, de Barra E, Havelock T, Bowyer G, Poulton ID, de Cassan S, Longley R, Illingworth JJ, Douglas AD, Mange PB, Collins KA, Roberts R, Gerry S, Berrie E, Moyle S, Colloca S, Cortese R, Sinden RE, Gilbert SC, Bejon P, Lawrie AM, Nicosia A, Faust SN, Hill AV.

J Infect Dis. 2015 Apr 1;211(7):1076-86. doi: 10.1093/infdis/jiu579. Epub 2014 Oct 21.

13.

4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaques.

Spencer AJ, Furze J, Honeycutt JD, Calvert A, Saurya S, Colloca S, Wyllie DH, Gilbert SC, Bregu M, Cottingham MG, Hill AV.

PLoS One. 2014 Aug 20;9(8):e105520. doi: 10.1371/journal.pone.0105520. eCollection 2014.

14.

Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs.

Busquets N, Lorenzo G, López-Gil E, Rivas R, Solanes D, Galindo-Cardiel I, Abad FX, Rodríguez F, Bensaid A, Warimwe G, Gilbert SC, Domingo M, Brun A.

Antiviral Res. 2014 Aug;108:165-72. doi: 10.1016/j.antiviral.2014.05.020. Epub 2014 Jun 14.

PMID:
24933081
15.

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

Kimani D, Jagne YJ, Cox M, Kimani E, Bliss CM, Gitau E, Ogwang C, Afolabi MO, Bowyer G, Collins KA, Edwards N, Hodgson SH, Duncan CJ, Spencer AJ, Knight MG, Drammeh A, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Soipei P, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Chilengi R, Bojang K, Flanagan KL, Hill AV, Urban BC, Ewer KJ.

Mol Ther. 2014 Nov;22(11):1992-2003. doi: 10.1038/mt.2014.109. Epub 2014 Jun 16.

16.

External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance.

Murphy SC, Hermsen CC, Douglas AD, Edwards NJ, Petersen I, Fahle GA, Adams M, Berry AA, Billman ZP, Gilbert SC, Laurens MB, Leroy O, Lyke KE, Plowe CV, Seilie AM, Strauss KA, Teelen K, Hill AV, Sauerwein RW.

PLoS One. 2014 May 16;9(5):e97398. doi: 10.1371/journal.pone.0097398. eCollection 2014.

17.

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.

Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, Gilbert SC.

Mol Ther. 2014 Mar;22(3):668-74. doi: 10.1038/mt.2013.284. Epub 2013 Dec 30.

18.

Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.

Warimwe GM, Lorenzo G, Lopez-Gil E, Reyes-Sandoval A, Cottingham MG, Spencer AJ, Collins KA, Dicks MD, Milicic A, Lall A, Furze J, Turner AV, Hill AV, Brun A, Gilbert SC.

Virol J. 2013 Dec 5;10:349. doi: 10.1186/1743-422X-10-349.

19.

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.

Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AV.

Nat Commun. 2013;4:2836. doi: 10.1038/ncomms3836.

20.

A multi-antigenic adenoviral-vectored vaccine improves BCG-induced protection of goats against pulmonary tuberculosis infection and prevents disease progression.

Pérez de Val B, Vidal E, Villarreal-Ramos B, Gilbert SC, Andaluz A, Moll X, Martín M, Nofrarías M, McShane H, Vordermeier HM, Domingo M.

PLoS One. 2013 Nov 21;8(11):e81317. doi: 10.1371/journal.pone.0081317. eCollection 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk